ALXN1840
Sponsors
Alexion Pharmaceuticals, Inc.
Conditions
HealthyWilson Disease
Phase 1
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
CompletedNCT04526210
Start: 2020-10-21End: 2021-05-28Updated: 2023-08-31
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
CompletedNCT04526197
Start: 2020-07-07End: 2020-11-03Updated: 2023-08-21
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
CompletedNCT04560816
Start: 2020-07-24End: 2021-03-24Updated: 2023-08-14
Copper Balance in Healthy Participants Administered ALXN1840
CompletedNCT04594252
Start: 2020-07-01End: 2020-11-18Updated: 2024-08-19
Bioavailability Study of 2 Oral Formulations of ALXN1840
CompletedNCT04610580
Start: 2021-01-31End: 2021-04-26Updated: 2024-01-16
Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
CompletedNCT05303324
Start: 2019-07-04End: 2019-10-09Updated: 2023-08-02
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
CompletedNCT05319899
Start: 2014-01-20End: 2014-03-24Updated: 2023-08-01
Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants
CompletedNCT05641311
Start: 2019-02-20End: 2019-05-02Updated: 2023-11-07
Phase 2
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
CompletedNCT02273596
Start: 2014-11-24End: 2018-11-07Updated: 2021-09-29
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
CompletedNCT04573309
Start: 2020-09-07End: 2022-06-07Updated: 2024-06-24
Phase 3
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
TerminatedNCT03403205
Start: 2018-02-22End: 2023-06-30Updated: 2024-06-17
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
TerminatedNCT05047523
Start: 2021-09-13End: 2023-06-26Updated: 2024-10-23